Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 9Terminated 5Active not recruiting 3Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Thoracic 1Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 33Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms, Castration-Resistant 2mCRPC 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Salivary Cancer 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Hormone Sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Melanoma 1Liposarcoma 1Lethal Congenital Contracture Syndrome 2 1Fibromatosis, Gingival, 2 1Esophageal Neoplasms 1Endometrial Neoplasms 1Dementia 1Colorectal Neoplasms 1Cognitive Dysfunction 1Castration-resistant Prostate Cancer Patients with Oligometastases 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 62Letrozole 55Fulvestrant 55Trastuzumab 50palbociclib 41pembrolizumab 37Cyclophosphamide 37Carboplatin 37Anastrozole 37pertuzumab 35exemestane 25Tamoxifen 24Capecitabine 24ribociclib 23abemaciclib 23Radiotherapy 21Docetaxel 21olaparib 20Doxorubicin 20Magnetic Resonance Spectroscopy 19trastuzumab deruxtecan 17Surveys and Questionnaires 17durvalumab 16Epirubicin 16Specimen Handling 14Exercise 14130-nm albumin-bound paclitaxel 14Taxes 13Alpelisib 13Goserelin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Breast Neoplasms × enzalutamide × Clear all
NCT04557449 2025-10-01

CDK4i

Pfizer

Phase 2 Active not recruiting
362 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

NCT02955394 2025-07-09

Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

University of Colorado, Denver

Phase 2 Active not recruiting
61 enrolled 12 charts
Breast

Breast Neoplasms

NCT02750358 2025-06-22

Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
50 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡